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Abstract
Deaths due to atherothrombosis are increasing throughout the world except in the lowest
socio-demographic stratum. This is despite 60 years of study and expenditure of billions of
dollars on lipid theory. Nevertheless, mainstream atherothrombosis theory persists even
though it has failed numerous tests. Contrary data are ignored, consistent with the practice of
science as envisioned by Thomas Kuhn. This paper examines defects in mainstream
atherogenesis theory and the flawed logic which allows its persistence in the face of what
should be obvious shortcomings.
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Introduction And Background
Charles Sydney Burwell, M.D., Dean of Harvard Medical School from 1935 to 1949, famously
said, “Half of what you are taught as medical students will in 10 years have been shown to be
wrong" [1]. Most medical students in the United States have heard this quote at least once. This
statement is supported by a study of 363 papers published in the New England Journal of
Medicine between the years 2001 and 2010 which found that 40.2% reversed a medical practice
while 38.0% reaffirmed it [2]. The fluid nature of best practice begs the question, “Why is the
medical mainstream resistant to a paradigm shift?” Informed by Thomas Kuhn’s theory of
paradigm shifts, historian of science Marc De Mey wrot,e “As long as paradigm-compatible
findings keep accumulating, it is rather easy to ignore or suppress discordant data as irrelevant
or just noisy elements [3].”
Dismissing discordant data is facilitated by unquestioned acceptance of a flawed theory and
faulty logic which is rarely recognized as such. In this review, the authors will first examine the
enlarging body of evidence which refutes lipid and inflammatory theories of atherothrombosis.
Then the authors examine the erroneous reasoning which perpetuates belief in mainstream
thought despite considerable conflicting evidence. Although this review focuses on
atherothrombosis, these errors can lead researchers astray and hinder progress in any field. 
Despite 60 years of study and an investment of billions of dollars, the rate of deaths due to
coronary artery disease is increasing in the United States and in all other countries except the
lowest socio-demographic populations worldwide (Figure 1, Figure 2) [4].
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FIGURE 1: Ischemic Heart Disease in the U.S.
Disability-adjusted life years lost (DALYs) per 100,000 due to ischemic heart disease in the
United States. Rates began to increase in 2011. Courtesy of the Institute for Health Metrics and
Evaluation.
FIGURE 2: Global Morbidity and Mortality Due to Ischemic
Heart Disease
Disability-adjusted life years (DALYs) per 100,000 due to ischemic heart disease stratified by
socio-demographic index (; a measure of per capita income, average educational attainment,
and fertility rate and in high income countries from 1990 to 2016. Rates for high income and
high and high-mid socio-demographic index countries decreased from approximately 2005
until roughly 2010 and then began to increase in approximately 2014. No increase was noted in
the low socio-demographic stratum. Courtesy of the Institute for Health Metrics and Evaluation.
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Deaths due to heart disease increased by 3% in the US between 2014 and 2015, the latest years
for which data are available [5]. Clearly, lipid theory is not powerful enough to provide the
insight necessary to control atherothrombosis.
Review
Mainstream atherothrombosis theory has failed numerous
tests
The essence of lipid or mainstream atherothrombosis theory is that cholesterol, cholesterol
ester, or some other component of low density lipoprotein (LDL) accumulates in the arterial
wall and elicits an inflammatory response which culminates in an atherosclerotic plaque.
Chronic oxidative stress is felt to be necessary to modify LDL so that it can be phagocytized by
macrophages via the scavenger receptor. High density lipoprotein (HDL) is felt to protect
against atherothrombosis by removing cholesterol from the periphery by "reverse transport"
and returning it to the liver for catabolism.
Antioxidant therapy, including Vitamin E supplementation, failed to alter cardiovascular risk
even though vitamin E prevents oxidative modification of LDL in vitro [6]. Inhibitors of
cholesteryl ester transfer protein (CETP), which raise HDL levels, failed to decrease
cardiovascular events in the following trials: the ILLUMINATE (Investigation of Lipid Level
Management to Understand its Impact in Atherosclerotic Events) trial using torcetrapib, the
dal-OUTCOMES trial assessing dalcetrapib, and the ACCELERATE (Assessment of clinical
effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high risk
for vascular outcomes) trial with evacetrapib. The failure of evacetrapib was particularly
surprising to the mainstream cardiology community because HDL-cholesterol levels increased
by 128% and LDL-cholesterol levels decreased by 35% in patients with an elevated risk for
cardiovascular disease [7]. The CETP inhibitors increase the size and number of HDL particles
which will increase blood viscosity [8]. The marginal efficacy of cholesterol-lowering therapy
was shown by Kristensen et al., who found that primary prevention with statin therapy resulted
in a median postponement of death by 3.2 days, and only 4.1 days in secondary prevention
trials [9]. Finally, and most significantly, DuBroff reported that 44 prospective, randomized
controlled studies of cholesterol-lowering therapy, three of which involved diet, showed no
mortality benefit despite reductions in LDL-cholesterol levels of up to 50%. Additionally, 30 of
these studies showed no reduction in cardiovascular events [10].
Two trials of anti-inflammatory therapy failed to show any benefit in preventing cardiovascular
disease. Losmapimod, which inhibits p38 mitogen-activated protein kinase, an enzyme which
amplifies the inflammatory cascade through enhanced production of TNF-α, IL-6, and other
cytokines, failed to improve outcome in the LATITUDE-TIMI 60 [Losmapimod to Inhibit p38
MAP (mitogen activated protein) Kinase as a Therapeutic Target and Modify Outcomes after an
Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 60] study [11]. Lipoprotein-
associated protein kinase is an enzyme hypothesized to cause atherogenesis and contribute to
plaque instability through pathways related to inflammation. Darapladib, an inhibitor of this
enzyme, failed to modify outcome in the SOLID-TIMI 52 (Stabilization of pLaques Using
Darapladib-Thrombolysis in Myocardial Infarction 52) trial [12]. The persistence of mainstream
atherothrombosis theory despite these negative results substantiate Kuhn’s assertion that
discordant findings are ignored by the mainstream.
The results of the recent CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes
Study) trial will be discussed below.
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Kuhnian dynamics in action
Dietary cholesterol was thought to play a role in atherothrombosis since Anitschskow induced
arterial lesions in rabbits by feeding them massive amounts of cholesterol. The observation by
Keys et al. that heart disease was more common in well-nourished businessmen than in the
malnourished population of World War II Europe, coupled with his 1953 report in which the
only variable that was higher in businessmen who suffered from heart disease was serum
cholesterol [13], established lipid theory as the mainstream paradigm.
Since the 1960s until recently, guidelines recommended limiting cholesterol consumption.
Now, overconsumption of cholesterol is recognized as not a cause for concern [14]. In 2014,
McNamara noted that changing the recommendations about cholesterol consumption was a
long, contentious process despite evidence which convinced objective nutritionists. He noted
that authorities in some countries experienced cognitive dissonance (i.e., performing an action
which is contrary to personal beliefs) and continued to promote outdated and potentially
hazardous dietary recommendation based on a refuted hypothesis [15].
There are many reasons for resistance to a paradigm shift. Scientists are not as dispassionate,
objective, and rational in processing information as computers. It is probably difficult for some
authorities to reverse a long-held position and admit that their previous advice was incorrect.
This may be especially true for clinicians who depend on their authority to encourage
compliance with their recommendations, and who might fear that a change in a long held
position will damage their credibility. The same may apply to prestigious institutions such as
the American Heart Association (AHA) and National Heart, Lung, and Blood Institute (NHLBI),
which are composed of numerous individual authorities. The imprimatur of these organizations
helped entrench lipid theory. Of particular importance in this regard is the National Cholesterol
Education Program (NCEP), a program of the NHLBI which has activities aimed at the public. In
addition, busy clinicians may not feel they have time to spend on a new theory which may not
stand the test of time, or enthusiasm for assimilating a new paradigm after working an 18-hour
day. It is not surprising that the physicist Max Plank wrote "a new scientific truth does not
triumph by convincing its opponents and making them see the light, but rather because its
opponents eventually die, and a new generation grows up that is familiar with it."
Conceptual errors surrounding mainstream atherothrombosis
theory
In 2002, Professor Emeritus P.J. Scott of the University of Auckland, New Zealand, wrote:
“Those who may seek now, or in the future, to denigrate the achievements of medical science in
the 20th century will find numerous examples within the general field of atherosclerosis
research of oversimplification, extrapolation, and near total abandonment of the principles of
the scientific method" [16]. We address these issues in the next sections.
Lipid Theory is Incomplete
An incomplete theory is one which explains only some, not all outcomes. It does not mean that
the theory is wrong, but it should not be considered as the final word. For example, Newtonian
mechanics is incapable of explaining the precession of the perihelion of planet Mercury, an
anomaly noted in 1859. However, the utility of the Newtonian laws of motion has never been
questioned because they have always provided useful results. It was only when Einstein
introduced the theory of general relativity that Mercury’s orbit was completely understood.
General relativity is a more complete theory.
Lipid theory is incomplete. It cannot explain the accelerated atherogenesis (i.e., development
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of an atherosclerotic plaque) associated with ageing, hypertension, diabetes mellitus, cigarette
smoking, exposure to fine particulate matter air pollution, hypercoagulability,
hypofibrinolysis, hyperfibrinogenemia, menopause, male gender, erythropoiesis stimulating
agents, deep venous thrombosis, elevated blood viscosity, elevated sedimentation rate,
decreased erythrocyte deformability, consumption of the Western diet and trans fats, lupus
anticoagulant, Protein C and S deficiencies, nephrotic syndrome, splenectomy, or sticky
platelet syndrome. It also is inadequate to explain the decreased atherogenesis associated with
aspirin use and clotting disorders such as von Willebrand disease and hemophilias. It should be
emphasized that the hematologic conditions in these lists affect the development of
atherosclerotic plaques, which are organized mural thrombi, as well as superimposed
thrombosis [17-19]. References demonstrating that hematologic disorders can cause
atherogenesis are provided in the Appendix. Further evidence of the limitation of lipid theory is
that only 30,000 of the estimated 100,000 excess annual myocardial infarctions in the US
attributable to the consumption of trans fats could be explained by lipid abnormalities [20].
Inflammatory theory is incomplete because it cannot explain the localization of atherosclerotic
plaques. 
Extrapolation
Extrapolation is the extension of the findings from a particular case to make a generalization
about all cases. Progress in atherothrombosis research is hindered by two examples of incorrect
extrapolation. First, extrapolating from familial hypercholesterolemia to conclude that
cholesterol causes atherothrombosis is incorrect. Second, the theory that atherothrombosis is
an inflammatory disease based on the accelerated disease in rheumatoid arthritis and other
true inflammatory diseases is also incorrect. The theories that hypercholesterolemia and
chronic inflammation cause atherothrombosis are limited or special cases of the broader theory
that elevated blood viscosity accelerates atherogenesis by promoting mural thrombosis [17-19].
Discussion of the role of elevated blood viscosity in atherothrombosis, metabolic syndrome,
diabetes mellitus type II, and slight elevations of C-reactive protein are beyond the scope of
this review. The interested reader is directed to references 17-19.
The recent CANTOS trial has been touted as a test of the inflammatory etiology of
atherothrombosis. Subjects who received 150 mg of canakinumab, a monoclonal antibody
against interleukin-1b, had a 14% decrease in myocardial infarction, stroke or fatal
cardiovascular event after 3.7 years [hazard ratio: 0.85 (95% CI, 0.74 to 0.98; P = 0.021)] [21].
Importantly, in a phase IIb trial, canakinumab therapy decreased plasma fibrinogen levels 21%,
from 330 mg/dL to 260 mg/dL, both normal values [22]. Fibrinogen is an independent risk factor
for atherothrombosis and increases blood viscosity. Therefore, it is possible that the benefit of
canakinumab therapy is due to decreased fibrinogen concentrations and blood viscosity, not
due to decreased inflammation. Unfortunately, fibrinogen concentrations were not reported in
Phase III of the CANTOS study.
The accelerated atherothrombosis associated with true chronic inflammatory diseases can be
explained by increased blood viscosity due to hyperfibrinogenemia, hypergammaglobulinemia,
and immune complexes. Fibrinogen augments erythrocyte aggregation, which elevates the
erythrocyte sedimentation rate and blood viscosity at low shear rates. IgM molecules are also
large enough to foster erythrocyte aggregation. Increased protein concentrations from any
cause will increase plasma viscosity and may foster erythrocyte aggregation via the “depletion”
force. This force drives erythrocytes together when protein concentrations surrounding
erythrocytes are greater than that found between them.
Falsification and Falsifiability Are Ignored
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The renowned philosopher of science Sir Karl Popper felt that the essence of a scientific theory
is that it should be falsifiable. A scientific theory should make specific predictions which can be
tested. A theory is refuted if testing fails to confirm these predictions. Popper also wrote “It is
easy to obtain confirmations, or verifications, for nearly every theory—if we look for
confirmations" [23]. Thus, in the scientific method as conceptualized by Popper, a theory can
only be disproved, not proved. No number of confirmations can ever prove a theory.
Popper’s work sheds light on studies of statin therapy. While statins have been shown to
reduce morbidity and mortality from atherothrombosis in some studies, DuBroff’s work shows
that they have failed in a substantial number of studies despite significantly decreasing LDL
levels. This failure falsifies the theory that elevated LDL or cholesterol is the cause of
atherothrombosis. However, some positive results of statin therapy are expected because high
LDL levels can increase blood viscosity, as in familial hypercholesterolemia. Data from the
Framingham study show that only 27% of attributable risk for coronary heart disease in men
and 34% in women are due to hypercholesterolemia [24]. In the Copenhagen Heart Study,
hypercholesterolemia was the sixth strongest variable in determining the relative risk of
coronary heart disease [25]. Data collected by the Asia Pacific Studies Collaboration showed
that the fraction of fatal coronary heart disease attributable to high cholesterol ranged from 0
to 14% in the 16 reporting counties [26]. These data are consistent with the theory that LDL is
only one of the multiple contributors to elevated blood viscosity and atherothrombosis.
Further, elevated LDL concentrations are a weak risk factor, resulting in a large number of
failed trials. Because a minority of cases of atherothrombosis is caused by elevated LDL, a
positive outcome is expected in some but not all studies of statin use in atherothrombosis.
Apologists for lipid theory consistently claim that lower concentrations of LDL are better for
preventing atherothrombosis. In dismissing a negative result, apologists can always argue that
cholesterol was not reduced sufficiently. By this argument, excluding LDL as the cause of
atherothrombosis will require finding the disease in someone with no lifetime exposure to LDL,
clearly an impossibility. Excluding cholesterol as the cause is also impossible because it is a
component of all animal cell membranes. For all practical purposes, these arguments render
the notion that LDL or cholesterol is the cause of atherothrombosis nonfalsifiable and
unscientific. Excluding LDL or cholesterol as the cause is a Sisyphean task at best and
unnecessary by the scientific method, which only requires refutation.
The cholesterol which is thought to elicit the chronic inflammation that causes
atherothrombosis is contained within foam cells in fatty streaks. Even the mainstream
recognizes that for unknown reasons only some fatty streaks progress, yet another non-
falsifiable belief. In this case, mainstream atherothrombosis theory persists because a
particular segment of artery can be studied histopathologically only once. Fatty streaks are flat
and cannot be detected radiologically.
Clinical trials of antioxidant vitamins and immunohistopathology refute oxidation theory.
Immunohistopathology shows that oxidized LDL does not cause monocyte chemotaxis,
cytotoxicity, or apoptosis as suggested by in vitro studies [27]. The persistent belief in the role
of chronic oxidative stress in atherothrombosis can be attributed to the dominance of lipid
theory and non-falsifiable defense of the oxidation hypothesis. After refutation in clinical
trials, two prominent proponents of the oxidation hypothesis wrote:
“The hypothesis that oxidative modification of LDL plays a significant role in
atherogenesis in humans is not necessarily disproved by the failure of these particular
clinical trials any more than a negative trial of an ineffectual antibiotic in Pneumococcal
pneumonia would prove that pneumonia is not a bacterial disease. The oxidative
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modification hypothesis is not that vitamin E will ameliorate the human disease but
that oxidative modification of LDL and/or other oxidative events play a significant role
in human atherogenesis as it does in animal models of atherogenesis. A corollary of the
hypothesis is that some appropriate antioxidant intervention, at some appropriate
dosage, in appropriately selected patients over an appropriate time interval has the
potential to improve prognosis [28]. 
This paragraph contains numerous non-falsifiable statements meant to prevent refutation of
oxidation theory, which is an ad hoc modification of lipid theory. Obviously, no observations
are excluded by these vague statements. As weak as it is, such an argument is sufficient to
defend an accepted hypothesis. To regain standing as a scientific hypothesis, a specific
falsifiable statement about oxidation theory must be made.
Ad Hoc Modifications
Ad hoc modifications are changes to a hypothesis which prevent its refutation. Sir Karl Popper
held a negative view about ad hoc modifications, writing “Such a procedure is always possible,
but it rescues the theory from refutation only at the price of destroying, or at least lowering, its
scientific status [23].” Oxidation theory is an ad hoc modification made necessary when it was
shown that uptake of cholesterol by the LDL receptor was insufficient to form a macrophage
foam cell because of negative feedback. However, chemically-modified LDL can be taken up by
the scavenger receptor in sufficient quantities to create a foam cell. Oxidation theory has been
refuted as discussed above.
Reverse transport of cholesterol is an ad hoc modification added to explain the protective effect
of HDL. Unmodified reverse transport theory is refuted by the rarity of atherothrombosis in
some subjects with extremely low levels of HDL due to lecithin:cholesterol acyltransferase
deficiency [29] and the failure CETP inhibitors, which elevate HDL levels. This has led to yet
another ad hoc modification, “dysfunctional HDL.” Some in vitro evidence has been offered in
support of this belief. These data should be treated with skepticism because it has been shown
very recently that both increased and decreased activity of putative markers of HDL function
can be seen when macrophages are incubated with HDL that was not stored in the presence of
cryoprotectants [30]. For the belief in HDL function to qualify as a hypothesis, a specific
molecular defect in dysfunctional HDL should be identified and studied prospectively to
determine if this defect increases the risk of atherothrombosis. 
There are several possible reasons for the uncritical acceptance of lipid theory. The
endorsement of the theory by funding organizations like the NHLBI and AHA is a conspicuous
reason. Lack of training in the scientific method is another possibility. Most scientists are aware
that accepting a p value of 0.05 as significant means that there is a 5% chance of incorrectly
rejecting the null hypothesis. Thus, someone under the impression that discordant finds are
rare may dismiss them as statistical outliers and not shortcomings of the theory. The work of
DuBroff et al. [10] shows that discordant data are too common to be dismissed and must be
considered a shortcoming in lipid theory. 
Fallacies which perpetuate acceptance of mainstream atherothrombosis theory
The next section is inspired by Follies & Fallacies in Medicine by Petr Skrabanek and James
McCormick [31]. 
The “Fallacy of Association Being Causal” and the “Fallacy of the Simple Explanation”
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Although most physicians and scientists know causality cannot be proven from an association,
it is not clear that this knowledge is exercised as widely as it should be. For example,
hypercholesterolemia or elevated plasma LDL concentrations are widely assumed to cause
atherothrombosis, and slight elevations of C-reactive protein are assumed to make
atherothrombosis an inflammatory disease. Rather than falling into the trap of accepting
causality when an association is noted between two common conditions, prudence, caution,
and intellectual rigor should prompt a search for a factor which causes both, such as elevated
blood viscosity [20]. Physicians are not the only ones who may accept an idea because it offers a
simple solution to a complex problem. This urge should be tempered because as H.L. Menken
observed, “for every complex problem there is a solution that is simple, direct, and wrong.” 
The “Weight-of-evidence Fallacy”
To date, germ theory, general relativity, cell theory, heliocentric theory, and plate tectonics are
supported by all available data, not just the bulk. Obviously, explaining all observations should
be the goal of every theory. By this standard, lipid theory is clearly wanting. The “weight-of-
evidence fallacy” refers to the belief that the majority of evidence determines truth. This fallacy
is widely used to support lipid theory, even appearing in the title of lipidologist Daniel
Steinberg’s defense of lipid theory, The Cholesterol Wars: Cholesterol Skeptics vs. the Bulk of
Evidence. This fallacy is also seen in the following quotation:
“The suggestion that the ‘limited success of cholesterol-lowering therapy in numerous
prospective randomized controlled studies, some of which show significant decreases in
serum LDL cholesterol but no improvement in outcome’ refutes the causal effect of LDL
on the risk of ASCVD [atherosclerotic cardiovascular disease] is not a quantitatively
literate argument. Instead, a synthesis of the totality of the evidence … provides
overwhelming quantitative evidence that LDL causes ASCVD… [32].”
Regarding the weight of evidence fallacy, Skrabanek and McCormick wrote: “Such an approach
to establishing truth is nonscience: not only is it nonscience; it is also dangerous, because
reasoning of this sort may lead to action that (particularly in the field of preventive medicine)
can touch many people's lives [31].” The danger of accepting lipid theory is that it makes the
search for a better theory unnecessary.
Awareness of certain ideas may have suggested that a preponderance of evidence is sufficient to
determine truth, or that eliminating discrepant observations is impossible. Clinicians and
researchers are aware of biological variability. Because of biological variability, not all humans
respond to an intervention in the same way. Further, an individual patient will not react as
predictably or reproducibly as a molecule will. The concept of fuzzy logic became widely
accepted in the 1970s. According to fuzzy logic, values of truth exist as a continuum between
completely true and completely false. Awareness of this concept, misinterpreted and
misapplied, could make workers comfortable with accepting a preponderance of data as
determining truth. The Heisenberg uncertainty principle states that there is a finite limit to
which the precision of certain pairs of variables, such as position and momentum, can be
known. The concept of a limit to precision could also make workers comfortable with settling
for a preponderance of data to determine truth. Finally, the Copenhagen interpretation of
quantum mechanics is typically presented to the public by non-physicists as “a cat can be both
dead and alive at the same time.” This concept, in conjunction with the uncertainty principle,
could foster the notion that some phenomenon cannot be completely known, making a
preponderance of data perhaps the best scientists can hope for.
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There are three major reasons why judging truth by the weight of evidence can lead to the
wrong conclusion. First, the majority of researchers, by definition, are always working within
the mainstream paradigm. These workers are unlikely to boldly question the mainstream
paradigm. Further, they are likely to interpret experimental findings within the framework of
the mainstream paradigm, not in a different light. Second, it is easy to obtain confirmations for
nearly every theory, as noted by Popper. Finally, it is possible to misinterpret even a large body
of evidence, as was the case in Eijkman’s theory of the cause of beriberi.
Christiaan Eijkman won the Nobel Prize in 1929 for his discovery of thiamine while
investigating the cause of beriberi. Eijkman initially hypothesized that beriberi was caused by a
microbe, influenced by the newly discovered germ theory and his training with the great
bacteriologist Robert Koch. At that time, some physicians thought all disease might be caused
by germs. Further, the pattern of outbreaks, involving housing such as prisons, ships, insane
asylums, and impoverished neighborhoods, suggested contagion through poor hygiene. When
Eijkman noticed that chickens fed with polished rice developed beriberi and recovered when
fed unpolished rice, he came to believe that rice grains contained an antitoxin and that the rice
sheath contained the antitoxin [33]. To test his hypothesis, he studied over 300,000 prisoners at
101 sites, and ruled out other factors which might be vectors for infectious disease. The data
showed that consumption of unpolished rice prevented beriberi, and seemed to confirm
Eijkman’s hypothesis. The disease was subsequently controlled by changing diets. In his paper,
"The Epistemology of Error", Douglas Allchin wrote: "Though Eijkman’s conclusions fit the
evidence, they were not necessarily free from error. Other interpretations, outside Eijkman’s
conceptual horizon, were also possible. Eijkman’s successor in Java, Gerrit Grijns, saw the
opposite gestalt: namely, something was missing rather than something present. … Contrary
explanations, here, each fit the available evidence [34].” 
Eijkman’s work resulted in the control of beriberi, even though his hypothesis about its cause
was incorrect. A massive study did not correct the mistake. Parallels between the research into
the cause of beriberi and the current state of atherothrombosis research include more than one
explanation which can explain the available evidence, a large-scale study which seems to
confirm the erroneous hypothesis (multiple studies in the case of atherothrombosis) and a true
explanation which is beyond the conceptual horizon of most. Even though the true cause of
atherothrombosis (i.e., promotion of mural thrombosis) is not recognized by the mainstream,
extrapolation from a special case (familial hypercholesterolemia) has led to a modestly
successful therapy. 
Given the resolve, resources, and an understanding of its pathogenesis, a disease can be
controlled. Witness the successes in controlling scurvy, polio, and hookworm disease. In the
case of atherothrombosis, the resolve and resources are present, but the understanding is
lacking. The limited success of lipid theory does not mean that atherothrombosis is an
exception, or beyond our ken. It merely shows that lipid theory is incomplete. It is time for a
paradigm shift.
Conclusions
In spite of extensive investigation into the role of lipids in atherothrombosis, the disease is not
controlled and death rates are increasing around the globe. This failure is due to shortcomings
of lipid theory. Lipid theory is incomplete because it does not explain the majority of cases of
atherothrombosis. The theory that hypercholesterolemia is the cause of atherothrombosis and
the theory that atherothrombosis is an inflammatory disease are examples of inappropriate
extrapolation. These theories are special cases of the general theory that increased viscosity
accelerates atherothrombosis by fostering mural thrombosis. Control of atherothrombosis will
require that lipid theory is superseded by a superior theory.
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Appendices
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